Millipore in sale discussions with “potential bidders”
This article was originally published in Clinica
Bioscience research tools developer Millipore has confirmed that it is pursuing strategic alternatives, adding fuel to rumours that Thermo Fisher is about to make a $6bn offer for the firm. Millipore (Billerica, Massachusetts) said that its board of directors was aiming to enhance shareholder value by seeking options such as the possible merger or sale of the company. Earlier this week, Millipore shares rocketed to their highest ever value in response to rumours of a takeover from Thermo (www.clinica.co.uk, February 24 2009).
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals